Predicting Early Death in Head and Neck Cancer—A Pilot Study

Cancers, Год журнала: 2025, Номер 17(2), С. 302 - 302

Опубликована: Янв. 17, 2025

Background: The aim of this study was to evaluate biomarkers and biological characteristics tumor biopsies from patients with head neck cancer (HNC) assess the risk early death. Furthermore, we analyzed whether any combination markers could be used for prognostication death within six months after diagnosis. Materials Methods: Patients diagnosed HNC, receiving curative treatment decision at a multidisciplinary board meeting, who died diagnosis were included in study. Nine identified matched according site stage seventeen survived least two years. Results: expression compared between early-death survivors. There significantly higher Ki-67 than those surviving years, mean difference 21% (p = 0.038). A significant cytoplasmic survivin noted where had increased survivors 0.021). intensity staining differed groups 0.006). Conclusions: results pilot indicate that Ki67 potential prognostic HNC possibly panel value making.

Язык: Английский

---

Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Янв. 28, 2025

Abstract Background Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive cancer with a median overall survival of only 12 months. Existing biomarkers have limited ability to predict treatment response or survival, exposing many patients the potential toxicity without certain clinical benefit. Circulating tumor DNA (ctDNA) has emerged as non-invasive, real-time biomarker that could address these challenges. Methods We analyzed 137 plasma samples from 16 R/M HNSCC undergoing immune checkpoint blockade (ICB)-based therapy. A tumor-informed, highly sensitive next-generation sequencing liquid biopsy assay (RaDaR, NeoGenomics Laboratories, Inc.) was applied track ctDNA changes at baseline throughout treatment. Univariable multivariable analyses were used assess association between negativity key outcomes: disease control (best objective stable disease, partial response, complete response), three-year (OS), progression-free (PFS). also assessed machine learning model progression based on dynamics. Results Multivariable analysis revealed during significantly associated improved (OR 21.7, 95% CI 1.86-754.88, p=0.0317), OS (HR 0.04, 0.00-0.47, p=0.0103), PFS 0.03, 0.00-0.37, p=0.0057). The predicted 88% accuracy (AUC 0.89). Conclusion Serial monitoring control, in receiving ICB, suggesting incorporation into practice enhance decision-making for clinicians improve patient outcomes.

Язык: Английский

---

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing

International Journal of Clinical Oncology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 7, 2025

Although the 5-year relative survival rates for resectable solid tumors have improved over past few years, risk of postoperative recurrence necessitates effective monitoring strategies. Recent advancements in molecular residual disease (MRD) testing based on circulating tumor DNA (ctDNA) analysis shown considerable promise context predicting recurrence; however, significant barriers to widespread clinical implementation remain-mainly, low awareness among healthcare professionals, high costs, and lack standardized assays comprehensive evidence. This position paper, led by Japan Society Clinical Oncology, aims establish a common framework appropriate use MRD type-agnostic manner. It synthesizes currently available evidence, reviews region-specific trends, addresses critical questions related testing, offers recommendations guide biotechnology pharmaceutical companies, regulatory authorities. These were developed voting process involving 15 expert members, ensuring consensus-driven approach. findings underscore importance collaborative efforts various stakeholders enhancing utility testing. project aimed foster consensus provide clear guidelines support advancement precision medicine oncology improve patient outcomes perioperative care.

Язык: Английский

---

Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay

Nature Communications, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 21, 2025

Язык: Английский

---

Emerging Proximal Liquid Biopsy Approaches for Detecting Residual Disease and Predicting Recurrence in Head and Neck Cancer: A Review and Proposal of Novel Liquid Staging

Head & Neck, Год журнала: 2025, Номер unknown

Опубликована: Март 21, 2025

Head and neck squamous cell carcinoma remains challenging due to high recurrence rates poor survival outcomes. Developing precise technologies for disease burden assessment, treatment response, minimal residual (MRD) surveillance is crucial improving prognosis. This review explores the potential of liquid biopsy MRD detection. A novel TNM (LiTNM) staging system introduced, integrating biomarkers from saliva, surgical drain lymphatic fluid (SLF), peripheral blood. Proximal biopsies, particularly saliva SLF, offer advantages their proximity tumor microenvironment. Saliva demonstrates sensitivity in HPV-associated oropharyngeal cancers, while SLF holds identifying early postoperative recurrence. Despite these advancements, standardization validation remain challenges. Liquid approaches show promise monitoring, yet clinical implementation stages. The proposed LiTNM could complement by providing a molecular framework risk stratification. However, rigorous prospective studies are necessary validate its utility facilitate adoption.

Язык: Английский

---